Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination

• Published in: Revista española de salud pública Vol. 74; no. 4; pp. 397 - 403
• Main Authors: Gutiérrez Rodríguez, M A, Ramírez Fernández, R, García Gutiérrez, J, Moreno Civantos, A, Hernando García, M, Arce Arnáez, A, Sendra Gutiérrez, J M, Bueno Vallejos, R
• Format: Journal Article
• Language: Spanish
• Published: Spain 01.07.2000
• Subjects: Adolescent; Adult; Age Distribution; Child; Child, Preschool; Disease Outbreaks - prevention & control; Humans; Incidence; Infant; Meningococcal Infections - epidemiology; Meningococcal Infections - microbiology; Meningococcal Infections - prevention & control; Meningococcal Vaccines - administration & dosage; Neisseria meningitidis - classification; Spain - epidemiology; Spain
• ISSN: 1135-5727

In 1997 (between 22 September and 14 November) an A + C meningococcal mass vaccination campaign was carried out in Madrid, targeting the age group of from 18 months to 19 years of age, in the face of an increase in the number of cases of meningococcal disease caused by serogroup C occurring in the 1996-97 season. This study forms a part of the impact assessment of that campaign. The evolution of the meningococcal disease, by means of the comparison of rates of incidence; and the efficacy of the vaccination campaign was determined after one year (1997-98 season) and after two years (1997-98 and 1998-99 seasons) of monitoring. The vaccine efficacy has been calculated as [1-(Incidence rate in vaccinated/Incidence rate in unvaccinated)]* 100. A significant drop was registered in the incidence of serogroup C meningococcal disease on comparing the 1997-98 and 1998-99 seasons with the epidemic season (1996-97). The vaccine efficacy after two years of monitoring subsequent to the vaccination campaign was 76.9% for the global population between 18 months and 19 years of age and 88.5% in the group of vaccinated individuals between 15 and 19 years of age. The vaccine efficacy obtained is compatible with that described in the relevant literature. The significant reduction in the incidence of meningococcal disease caused by serogroup C was due to the vaccine efficacy obtained.